TCON — TRACON Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $0.15m
- -$6.12m
- $12.05m
Brief: Runway Growth Finance Corp Provides Fourth Quarter 2022 Portfolio Update
Brief: Tracon Pharmaceuticals Inc - As Of Dec 31, 2022 Sees Cash Runway Till Mid-2023
Brief: TRACON Pharmaceuticals Receives Notice Of Delisting From Nasdaq
Brief: Tracon Pharmaceuticals Announces Up To $30 Mln Financing Related To Arbitration Award Decision Expected In Q1 2023
Brief: TRACON Announces Positive Results For Cancer Therapy From The Ongoing Phase 2 Trial
Tracon Pharmaceuticals Inc Reports Results For The Quarter Ended In September: Earnings Summary
Brief: TRACON Pharmaceuticals Reports Third Quarter 2022 Financial Results
Tracon Pharmaceuticals Inc Expected To Post A Loss Of 28 Cents A Share: Earnings Preview
Brief: TRACON To Report Q3 2022 Financial Results And Provide Corporate Update On November 14, 2022
Tracon Pharmaceuticals Inc Expected To Post A Loss Of 28 Cents A Share: Earnings Preview
U.S. STOCKS ON THE MOVE-Alphabet, Sylvamo, Compass
U.S. STOCKS ON THE MOVE-Pinterest, Take-Two, energy sector
TRACON Pharma up on positive review for cancer antibody trial
Brief: TRACON Pharmaceuticals Announces Results Of Independent Data Monitoring Committee Review Of 12 Week Safety Data From Envasarc Phase 2 Pivotal Trial - Trial To Proceed As Planned
Brief: Tracon Pharmaceuticals Announces Fast Track Designation By The FDA For Envafolimab For The Treatment Of The Soft Tissue Sarcoma Subtypes Of Ups And Mfs
Refile: BUZZ-Tracon Pharma up on FDA fast track designation for cancer drug
U.S. STOCKS ON THE MOVE-Envista, Bed Bath & Beyond, United Parcel Service
U.S. STOCKS ON THE MOVE-Astra Space, Ammo, Chimerix
Tracon Pharma jumps on FDA nod for rare cancer treatment study